3 recruiting, 2 active not recruiting, 2 completed, 1 withdrawn. 4 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Lymphomatoid Papulosis: new trials by email Literature Review of Lymphomatoid Papulosis trials Research Report on Lymphomatoid Papulosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis Lymphomatoid Papulosis, Mycosis Fungoides | Recruiting | M.D. Anderson Cancer Center | 100 | 2024-01-19 | 2026-07-16 | |
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. Med-Jet Injector, Triamcinolone Acetonide, Bexarotene 1% Top Gel - Mycosis Fungoides of Skin (Diagnosis), Cutaneous T-cell Lymphoma | Not applicable | Withdrawn | Case Comprehensive Cancer Center | 2022-04-01 | 2025-06-12 | |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 43 | 2018-10-29 | 2026-06-12 |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients brentuximab vedotin - Mycosis Fungoides, Lymphomatoid Papulosis | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 58 | 2018-07-03 | 2026-04-03 |
| Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma | Phase 2 | Completed | John Reneau | 26 | 2018-03-16 | 2026-08-13 |
| Tissue Repository: CTCL Collection Protocol Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis | Recruiting | Columbia University | 400 | 2016-07-01 | 2025-11-04 | |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) SGN-35 - CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 79 | 2011-06-01 | 2026-07-16 |
| Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma SGN-30 - Large Cell Lymphoma | Phase 2 | Completed | Seagen Inc. | 40 | 2004-09-01 | 2014-12-18 |
Lymphoma, T-Cell, Cutaneous (5) · Mycosis Fungoides (4) · Lymphoma, Primary Cutaneous Anaplastic Large Cell (3) · Lymphoma (2) · Lymphoma, T-Cell (2) · Sezary Syndrome (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Disease (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma, Follicular (1) · Lymphoma, Large-Cell, Anaplastic (1)
Hemic and Lymphatic Diseases (8) · Neoplasms by Histologic Type (8) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Lymphatic Diseases (7) · Lymphoma, Non-Hodgkin (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Lymphoma (6) · Lymphoma, T-Cell (6) · Lymphoma, T-Cell, Cutaneous (3) · Histiocytic Disorders, Malignant (1) · Histiocytosis (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Brentuximab Vedotin (4) · Bendamustine Hydrochloride (1) · Bexarotene (1) · Lenalidomide (1) · Mechlorethamine (1) · Triamcinolone Acetonide (1) · fludarabine (1)
M.D. Anderson Cancer Center (2) · Case Comprehensive Cancer Center (1) · Columbia University (1) · John Reneau (1) · Memorial Sloan Kettering Cancer Center (1) · Seagen Inc. (1) · UNC Lineberger Comprehensive Cancer Center (1)
United States (8)
Alison Moskowitz, MD (1) · Auris O Huen, MD (1) · John Reneau, MD (1) · Julia Dai, MD (1) · Kevin Cooper, MD (1) · Larisa J. Geskin, MD (1) · Natalie Grover, MD (1)
R01CA247497 (1)